Respiratory

Latest News


CME Content


The FDA ordered 4 companies to stop selling 44 of their flavored e-liquid and hookah tobacco products that lack the required approval for sale; CMS has yet to implement a 2014 law preventing unnecessary, expensive screening tests (magnetic resonance imaging, computed tomagraphy scans and other tests) that could harm patients and waste resources; Amarin, which is seeking FDA approval for an expansion of Vascepa labeling to include data that showed a 25% reduction in the risk of heart attacks and strokes, said the FDA has scheduled an advisory committee meeting for November 14.

US District Judge James E. Boasberg ruled that New Hampshire cannot move ahead with work requirements in exchange for Medicaid coverage; a study looking at 8 flavors of Juul e-liquids found the presence of acetals, irritating chemicals formed from alcohol and aldehydes, in the Crème brûlée flavor; Medicaid expansion advocates are petitioning Florida, Missouri, and Oklahoma to include ballot measures asking voters if they want to allow the federal healthcare program to cover more low-income adults.

While poor sleep quality is common in patients with interstitial lung disease (ILD), it is unclear which factors other than sleep disordered breathing may contribute to poor sleep quality for these patients. A study published in ERJ Open Research found that providers should target depression and coexisting sleep disorders in order to improve sleep quality and quality of life for patients with ILD.

Early detection and treatment of lung cancer through screening with low-dose computed tomography (CT) has been investigated as a potential tool for reducing lung cancer deaths, the leading cause of cancer death worldwide, for more than 2 decades. Published this week was an extended follow up study to the 2011 randomized National Lung Screening Trial that found a similar number of patients must be screened to prevent cancer deaths as determined in the original analysis.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo